WallStSmart
PFE

Pfizer Inc

NYSE: PFE · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$26.70
+1.68% today

Updated 2026-04-30

Market cap
$149.38B
P/E ratio
19.31
P/S ratio
2.39x
EPS (TTM)
$1.36
Dividend yield
6.50%
52W range
$21 – $29
Volume
38.0M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Pfizer Inc (PFE) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$26.70
Consensus
$28.57
+7.00%
2030 Target
$135.94
+409.14%
DCF
$37.19
+28.21% MoS
14 analysts:
4 Buy8 Hold4 Sell

Management guidance

No specific CEO revenue targets found in provided data. Latest analyst consensus (Feb-Apr 2026) projects FY2026 revenue of $61.84B (down 1.18% YoY) and FY2027 revenue of $59.63B (down 3.57% YoY). Company is executing cost-cutting initiatives including R&D footprint restructuring.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$229.39
$65.5B Rev × 20x P/S
Base case (2030)
$135.94
$65.5B Rev × 12x P/S
Bear case (2030)
$90.62
$65.5B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$59.6B$63.6B$62.6B$61.8B$59.6B$60.5B$62.8B$65.5B
Revenue growth—6.8%-1.6%-1.2%-3.6%1.5%3.8%4.3%
EPS$1.58$2.84$2.96$2.99$2.85$2.95$3.10$3.28
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$130.27$124.61$127.44$130.27$135.94

Catalysts & risks

Growth catalysts
+ Lyme disease vaccine regulatory approval (Phase 3 positive efficacy data reported March 2026, seeking FDA approval despite primary endpoint miss)
+ Next-generation CDK4 inhibitor (Ibrance successor atirmociclib) Phase 2 positive breast cancer data advancing development
+ TALZENNA prostate cancer expansion showing significant radiographic progression-free survival improvements
+ Pipeline advancement in oncology (strategic pivot area) with multiple mid-to-late stage programs
+ Potential tariff policy impact on imported drugs (Trump administration considering up to 100% pharma tariffs)
Key risks
- Sustained revenue decline: FY2025 down 1.65%, FY2026 guidance down another 1.18%, FY2027 down 3.57% - suggesting structural headwinds beyond COVID normalization
- Patent cliff and biosimilar competition eroding legacy product revenues (Ibrance, Prevnar facing competition)
- Pipeline execution risk: Lyme vaccine failed primary endpoint; multiple late-stage programs critical for growth
- Geopolitical/regulatory: Tariff policy uncertainty, international vaccine contract disputes (Poland/Romania €1.9B dispute), pricing pressure from Medicare negotiations
- Macroeconomic: High debt levels ($28.99B total debt vs. $162.4B market cap), elevated leverage limits financial flexibility

Methodology

Pfizer Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 14 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.